Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

BV + Len + R may be considered as a bridging therapy for patients with R/R DLBCL prior to chimeric antigen receptor-T or other more definitive ... v negative [<1%]), cell of origin (germinal center B ...

Newly developed vaccine could protect against emerging SARS-CoV-2 variants and related coronaviruses that may jump from ...

Researchers from the Massachusetts Institute of Technology (MIT) and the California Institute of Technology (Caltech) have made significant strides in vaccine development that could protect against ...

Oncologist Siddharth Mukherjee’s Immuneel holds out hope for those whose cancer fails to respond to other treatments ...

A new experimental vaccine developed by researchers could offer protection against emerging variants of SARS-CoV-2, as well ...